Effects of dipyridamole and adenosine infusions on ovine pulmonary and systemic circulations

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 272, Issue 2 41-2, 1997, Pages

  Skimming, Jeffrey W ^a   Demarco, Vincent G ^a   Cassin, Sidney ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

drug; phosphodiesterase; sheep; vascular resistance; vasodilation

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE; ADENOSINE A2 RECEPTOR; DIPYRIDAMOLE; PHOSPHODIESTERASE; THEOPHYLLINE; THROMBOXANE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEMODYNAMIC PARAMETERS; INTRAVENOUS DRUG ADMINISTRATION; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SHEEP; SYSTEMIC VASCULAR RESISTANCE; VASCULAR RESISTANCE; VASODILATATION;

EID: 33750861840     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1997.272.2.h921     Document Type: Article

References (29)

1. Afonso, S. Inhibition of coronary vasodilating action of dipyridamole and adenosine by aminophylline in the dog. Circ. Res. 26: 743-752, 1970.
2. Afonso, S., and G. S. O'Brien. Inhibition of cardiovascular metabolic and hemodynamic effects of adenosine by aminophylline. Am. J. Physiol. 219: 1672-1674, 1970.
3. Beavo, J. A., and D. H. Reifsnyder. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11: 150-155, 1990.
4. Bennet, D. W., and A. N. Drury. Further observations relating to the physiological activity of adenine compounds. J. Physiol. Lond. 72: 288-320, 1931.
5. Bretschneider, H., A. Frank, U. Bernard, K. Kochsiek, and R. Scheler. Die Wirkung eines Pyridmidopyrimidin-Derivates auf Sauerstoffversorgung des Herzmuskels. Arzneim. Forsch. 9: 49-59, 1959.
6. Bunag, R. D., C. R. Douglas, S. Imai, and R. M. Berne. Influence of a pyrimidopyrimidine derivative on deamination of adenosine by blood. Circ. Res. 15: 83-88, 1964.
7. Chen, Z. C., C. M. Kwan, and J. H. Chen. Profound shock resulting from a large dose of dipyridamole. Int. J. Cardiol. 46: 75-78, 1994.
8. Clarke, D. A., J. Davoli, F. S. Phillips, and G. B. Brown. Enzymatic deamination and vasodepressor effects of adenosine analogs. Am. J. Cardiol. 106: 291-302, 1995.
9. Clarke, W. R., S. Uezono, A. Chambers, and P. Doepfner. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm. Pharmacol. 7: 81-89, 1994.
10. Daly, J. W. Adenosine receptors: targets for future drugs. J. Med. Chem. 25: 197-207, 1982.
11. Daly, J. W., K. A. Jacobson, and D. Ukena. Adenosine receptors: development of selective agonists and antagonists. Prog. Clin. Biol. Res. 230: 41-63, 1987.
12. Daly, J. W., W. L. Padgett, and M. T. Shamim. Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituents. J. Med. Chem. 29: 1520-1524, 1986.
13. Drury, A. N., and A. Szent-Gyorgyi. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. Lond. 68: 213-237, 1929.
14. Gaddam, J. H., and P. Holtz. The localization of the action of drugs on the pulmonary vessels of dogs and cats. J. Physiol. Lond. 77: 139-158, 1933.
15. Gillespie, J. H. The biological significance of the linkages in adenosine triphosporic acid. J. Physiol. Lond. 80: 345-359, 1934.
16. Hamilton, H. W., M. D. Taylor, R. P. Steffen, S. J. Haleen, and R. F. Bruns. Correlation of adenosine receptor affinities and cardiovascular activity. Life Sci. 41: 2295-2302, 1987.
17. Homma, S., Y. Gilliland, T. E. Guiney, H. W. Strauss, and C. A. Boucher. Safety of intravenous dipyridamole for stress testing with thallium imaging. Am. J. Cardiol. 59: 152-154, 1987.
18. Johnston, D. L., J. R. Daley, D. O. Hodge, M. R. Hopfenspirger, and R. J. Gibbons. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2,000 patients. Mayo Clin. Proc. 70: 331-336, 1995.
19. Kalsner, S. Adenosine and dipyridamole actions and interactions on isolated coronary artery strips of cattle. Br. J. Pharmacol. 55: 439-445, 1975.
20. Koss, F. W., G. Beisenherz, and R. Maerkisch. Die eliminierung von Adenosine aus dem Blut unter dem Einfluss von 2,6-Bis (Diathanolamino)-4,8-Dipiperidino-Pyrimido (5,4-d) Pyrimidin und Papaverin. Arzneim. Forsch. 12: 1130-1131, 1995.
21. Londos, C., D. M. Cooper, and J. Wolff. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA 77: 2551-2554, 1980.
22. Lugnier, C., P. Schoeffter, A. Le Bec, E. Strouthou, and J. C. Stoclet. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35: 1743-1751, 1986.
23. Neely, C. F., D. M. Haile, B. E. Cahill, and P. J. Kadowitz. Adenosine and ATP produce vasoconstriction in the feline pulmonary vascular bed by different mechanisms. Am. J. Cardiol. 258: 753-761, 1991.
24. Nicholson, C. D., R. A. Challiss, and M. Shahid. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12: 19-27, 1991.
25. Schrader, J., R. Berne, and R. Rubio. Uptake and metabolism of adenosine by human erythrocyte ghosts. Am. J. Physiol. 223: 159-166, 1972.
26. Sollevi, A., J. Ostergren, B. Fagrell, and P. Hjemdahl. Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. Acta Physiol. Scand. 121: 165-171, 1984.
27. Thomas, M. K., S. H. Francis, and J. D. Corbin. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem. 265: 14964-14970, 1990.
28. Van Calker, D., M. Muller, and B. Hamprecht. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33: 999-1005, 1979.
29. Ziegler, J. W., D. D. Ivy, J. J. Fox, J. P. Kinsella, W. R. Clarke, and S. H. Abman. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am. J. Physiol. 269 (Heart Circ. Physiol. 38): H437-H479, 1995.